

# Hepatitis C Drugs: Putting Profits Before Patients; The CBCD Reviews a Government Report

*The makers of a breakthrough drug for hepatitis C infection put profits before patients in pricing the \$1,000-per-pill cure.” (1)*

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, January 14, 2016 /EINPresswire.com/ --

“Infected with the hepatitis C virus (HCV)? The CBCD recommends taking [Novirin](#) or [Gene-Eden-VIR](#).” - Greg Bennett, CBCD

A report released by the U.S. Senate Finance Committee found that the makers of a game changing drug against the hepatitis C virus (HCV) were focused more on financial gain than on the health of patients. “The report released Tuesday ... concludes that California-based Gilead Sciences was focused on maximizing revenue even as its own analysis showed a lower price would allow more patients to be treated for the liver-wasting disease.” (1)

As the San Francisco Chronicle noted, “With the hepatitis C virus affecting about 3 million people in the United States, the impact of Gilead’s pricing strategy is real, measurable — and devastating. With a 12-week course of Gilead’s Harvoni priced at nearly \$100,000, taxpayer-funded Medicare Part D spent \$4.6 billion on hepatitis C alone in the first half of 2015, leaving seniors and disabled persons with the prospect of higher deductibles and maximum out-of-pocket costs. Twenty-nine states said that hepatitis C was their most or second-most-costly pharmaceutical outlay, resulting in only 2.4 percent of affected Medicaid enrollees undergoing treatment.” (1)



It is clear then that new hepatitis C (HCV) drugs are too expensive for most patients. An article in Forbes magazine noted that these high costs “are hitting

wouldn't be able to afford the drug otherwise. Medicaid is funded by state and federal tax dollars and administered by state governments." (2)

"For those infected with the latent HCV, we recommend Novirin or Gene-Eden-VIR. The formula of these natural HCV remedies was shown to reduce hepatitis C symptoms in two separate post-marketing clinical studies that followed FDA guidelines." – Greg Bennett, CBCD

Click to learn more about [HCV symptoms](#).

The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Gene-Eden-VIR and Novirin formula is effective against the hepatitis C virus, and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, "individuals infected with HCV ... reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR." (3) The study authors also wrote that "we observed a statistically significant decrease in the severity, duration, and frequency of symptoms." (3)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites, here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

It is interesting to note that the Senate Finance Committee reported the following, "Gilead acquired access to its sofosbuvir-based drugs through a multi-billion dollar acquisition and spent hundreds of millions of dollars more completing clinical trials and FDA approvals. While there were extensive discussions regarding return on those investments while Gilead was considering the acquisition of Pharmasset, there is scant evidence that return on these investments played a significant role in determining the pricing of these drugs. Similarly, the cost of manufacturing Sovaldi, which was nominal, played no part in establishing the price. In an interview, Gilead executive Jim Meyers, who played a lead part in making the pricing recommendation did not know the cost of manufacturing the drug." (4)

What other treatments are currently available against the HCV virus?

Until recently, "the combination of a pegylated interferon (IFN)- $\alpha$  and ribavirin (was) the standard treatment for chronic HCV infections. This combination is effective in about 80% of the individuals infected with the HCV genotype 2 or 3, and in about 40% – 50% in those infected with genotype 1 or 4. Lately, two new drugs were approved, telaprevir and boceprevir, with better results. However, the combinations of pegylated interferon (IFN)- $\alpha$  and ribavirin and telaprevir or boceprevir are associated

with additional side effects, increased costs, and more complex treatment strategies.” (3) There are also newly approved drugs including Sovaldi, Harvoni, and Virkira Pak.

“Unlike these costly drugs, Novirin and Gene-Eden-VIR are natural remedies designed to target the latent HCV.” - Greg Bennett, CBCD

Find us on Facebook here: <https://www.facebook.com/GeneEdenVIR>

Follow us Twitter here: @HananPolansky

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

#### References:

(1) Pricy hepatitis C drugs threaten health care system (San Francisco Chronicle)

<http://www.sfchronicle.com/opinion/openforum/article/Pricy-hepatitis-C-drugs-threaten-health-care-6751291.php>

(2) Forbes.com - As Pricy Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles. Published October 10, 2014.

<http://www.forbes.com/sites/brucejapsen/2014/10/10/as-hepatitis-pill-harvoni-joins-sovaldi-states-erect-medicaid-hurdles/>

(3) Gene-Eden-VIR is Antiviral: Results of a Post marketing clinical study. Published in September 2013. scirp.org/journal/PaperInformation.aspx?PaperID=36101#.VE44nyKUf90

(4) "The Price of Sovaldi and Its Impact on the U.S. Health care System" - Committee on Finance United States Senate - U.S. Government Publishing Office, Washington. 2015

Greg Bennett  
CBCD  
585-250-9999  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.



